Boston Scientific Corporation (BSX)
What changed in recent filings
- Revenue +8% YoYQuarter ended Jun 30, 2026
- Institutions — 2 new · 7 added · 2 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Boston Scientific Corporation recent earnings releases
Based on SEC filings. The release date is the day the earnings filing (8-K) was accepted; for quarters where that filing was not found, the periodic report filing date is shown.
- 26Q2Released Jul 29, 2026Revenue +7.5% YoY · EPS $0.61Released before the open: Jul 28 close → Jul 29 close, the stock moved +0.0% · over the same window, market -1.5% · sector -0.4%
- 26Q1Released Apr 22, 2026Revenue +11.6% YoY · EPS $0.90Released before the open: Apr 21 close → Apr 22 close, the stock moved +9.0% · over the same window, market +1.0% · sector +0.1%
- 25Q4Released Feb 4, 2026Revenue +15.9% YoY · EPS $0.45Released before the open: Feb 3 close → Feb 4 close, the stock moved -17.6% · over the same window, market -0.5% · sector +0.1%
- 25Q3Released Oct 22, 2025Revenue +20.3% YoY · EPS $0.51Released before the open: Oct 21 close → Oct 22 close, the stock moved +4.0% · over the same window, market -0.5% · sector -0.1%
Institutions holding Boston Scientific Corporation
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 10 → 2026 Q2: 13 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Boston Scientific Corporation
Institutions we track that reported holding this stock in their most recent 13F.
- National Pension Service (Korea)0.11% of portfolio · held as of 2019 Q1 or earlier
- Dodge & Coxunder 0.01% of portfolio · held as of 2019 Q1 or earlier
- PRIMECAP Management1.28% of portfolio · held as of 2019 Q1 or earlier
- Caisse de depot (Quebec)0.19% of portfolio · held as of 2019 Q1 or earlier
- Bridgewater Associates0.08% of portfolio · since 2020 Q3
- Point72 Asset Management0.02% of portfolio · since 2021 Q3
- Capital World Investors0.08% of portfolio · since 2023 Q3
- Temasek Holdings (Singapore)0.27% of portfolio · since 2024 Q4
- Tudor Investment Corp0.09% of portfolio · since 2025 Q1
- Blackstone0.01% of portfolio · since 2025 Q3
- Maverick Capital2.24% of portfolio · since 2025 Q4
- Glenview Capital ManagementNew this quarter0.09% of portfolio · since 2026 Q2
- Moore Capital ManagementNew this quarter0.12% of portfolio · since 2026 Q2
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Q2 2026 13F recap — stocks several institutions bought and sold together →Company overview
Boston Scientific. A medical-device company in cardiac, endoscopy, and neuro fields, with stents, catheters, and neuromodulation devices as its mainstays. Regulatory approval and product innovation are the competitive keys.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Boston Scientific Corporation is classified under the Biotech & Health sector. See peers below.
Boston Scientific Corporation key financials
Based on SEC filings · as of Jun 30, 2026
Tap a metric name to see its meaning in the glossary.
Boston Scientific Corporation vs Biotech & Health sector benchmark
Median of 38 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
BSX revenue by segment summary
SEC 10-Q · segment totals cross-checked against total revenue
2026-06-30 revenue was $5.4B, +7.5% YoY.
The largest segment is Cardiovascular, 66.6% of revenue — a highly concentrated structure.
Recent revenue growth was led mainly by the Cardiovascular segment (about 73% of the increase).
Full segment weights, YoY changes, and an AI synthesis are available in the detailed analysis.
ETFs holding Boston Scientific Corporation
Per SEC N-PORT · 2026-06-30 · by weight · factual
BSX on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
BSX FAQ
What is Boston Scientific Corporation (BSX)?
Boston Scientific. A medical-device company in cardiac, endoscopy, and neuro fields, with stents, catheters, and neuromodulation devices as its mainstays. Regulatory approval and product innovation are the competitive keys.
What sector is Boston Scientific Corporation in?
Boston Scientific Corporation is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Boston Scientific Corporation's key financials?
As of Jun 30, 2026 in SEC filings: Revenue growth (YoY) 13.5%, Operating margin 21.6%, Net margin 17.5%, ROE 11.9%, Debt-to-equity 0.44x. Definitions and interpretation are available on Stocklore.
What are Boston Scientific Corporation's main revenue segments?
The largest segment is Cardiovascular, about 66.6% of revenue. Segment totals are cross-checked against total revenue from SEC filings.
Where can I analyze Boston Scientific Corporation (BSX) stock?
On Stocklore you can see BSX's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.